Full-Time

Vice President, Quality Assurance

Posted on 7/7/2025

CG Oncology

CG Oncology

51-200 employees

Develops bladder cancer oncolytic immunotherapies

Compensation Overview

$307k - $320k/yr

+ Annual Performance Bonuses + Equity

Remote in USA

Remote

Category
QA & Testing (1)
Requirements
  • Bachelor’s Degree in relevant/scientific field.
  • 15 years of progressively increasing quality leadership experience within the pharmaceutical industry required including interfacing regularly with Federal Drug Administration, Nuclear Regulatory Commission, and other regulatory bodies.
  • Minimum of 10 years of managerial experience, demonstrated history of experience leading people towards meeting the organization's vision, mission and goals by providing an inclusive workplace that fosters the development of others, facilitates cooperation and teamwork.
  • Experience leading regulatory agency inspections, ensuring compliance with policies, procedures and regulatory requirements, experience overseeing or acting as liaison for local, state, federal, and global regulatory agency inspections is required.
  • Significant work experience in a finished pharmaceutical cGMP manufacturing environment as well as radiopharmaceutical manufacturing is required as is experience in Clinical Quality Assurance activities.
  • Experience leading change within an organization is required.
Responsibilities
  • Plans and directs all aspects of the Quality Management Systems (QMS) throughout the organization, including GxP training and education, SOP's, master manufacturing records, specifications, equipment and process qualifications, analytical test reports, OOS investigations, non-conformance reports, CAPA's, change control system, supplier qualification, deviations, computerized electronic systems etc.
  • Accountable for the performance of the Quality Assurance team including compliance, measuring Key Performance Indicators, internal and external customer satisfaction, timely testing and release, labeling, relationships with regulators and customers, talent management, departmental budget and effective communications related to quality initiatives.
  • Assure compliance metrics are appropriate measures of life cycle and new product compliance. Conduct trend analysis of audit/inspection observations and communication of results expediently to applicable groups. Expedite key documentation processes requiring a high level of responsiveness for Exceptions, Out of Specification results, Corrective Actions and Preventative Actions.
  • Serve as a technical / quality system resource and actively collaborate with Manufacturing / R&D / PMO / Supply Chain / Regulatory Affairs and Medical / Commercial organizational counterparts making quality decisions for new project teams and life cycle product teams. This includes leadership on Quality by Design, Failure Mode & Effect Analysis, and Risk-Based Decision Making.
  • Optimize, manage the internal auditing program, and collaborate, cross-functionally, to ensure compliance; plan and execute compliance audits of internal operations as they relate to GxPs and drive timely completion of associated corrective actions.
  • Oversee the management of external and Health Authority inspections, ensuring compliance with policies, procedures, and regulatory requirements. Function as key liaison for local, state, federal, and global regulatory agency inspections. Proactively seek to affect change to reduce the number of observations identified during audits/inspections and ensure company is aligned with current regulatory expectations.
  • Oversee and review recommendations and implementation of improvements induced by new regulations, agency guidance documents, industry standards, modern technologies, and internal needs.
  • Conduct ongoing surveillance of worldwide regulations and establish procedures and policies to comply with everchanging regulatory environment. Maintain awareness of science and industry trends and integrate appropriately into work focus.
  • Drive Change Management Process, Materials Management Process and in-coming goods processes and support CG Oncology’s manufacturing as well as quality systems supporting Clinical Trial Material manufacture and release.
  • Manage CG Oncology’s QMS and Documentation Department responsible for the review / approval of a GxP procedures and records retention. This includes the company-wide training, determination of training needs against metrics, and management of employee training records. This also includes supporting computer system validation documentation and business continuity documentation needs.

CG Oncology develops immunotherapy treatments for bladder cancer, with a focus on preserving the bladder in patients with urologic cancers. Its lead product, cretostimogene grenadenorepvec, is delivered directly into the bladder to stimulate the immune system to attack non-muscle invasive bladder cancer that does not respond to BCG. The company concentrates on localized bladder cancer immunotherapy, differentiating itself by intravesical delivery and a focus on NMIBC, rather than broad systemic cancer drugs. Its goal is to improve quality of life for patients with NMIBC and other urologic cancers and move toward commercialization.

Company Size

51-200

Company Stage

IPO

Headquarters

Irvine, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • $903M cash funds operations into H1 2029 without dilution.
  • PIVOT-006 topline data expected H1 2026 accelerates approval path.
  • H.C. Wainwright targets $80/share citing strong safety data.

What critics are saying

  • FDA rejected cretostimogene BLA due to BOND-003 durability issues.
  • Merck's pembrolizumab captures 60% BCG-unresponsive NMIBC market.
  • $250M annual burn depletes cash by mid-2028 post-2026 readouts.

What makes CG Oncology unique

  • Cretostimogene grenadenorepvec delivers oncolytic immunotherapy intravesically for BCG-unresponsive NMIBC.
  • CG0070 targets Rb-defective bladder cancer cells via selective adenovirus replication.
  • First randomized Phase 3 trial in intermediate-risk NMIBC with PIVOT-006.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Unlimited Paid Time Off

401(k) Company Match

401(k) Retirement Plan

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Performance Bonus

Health Savings Account/Flexible Spending Account

Company News

Yahoo Finance
Mar 15th, 2026
CG Oncology shares up 131% in a year as DCF model suggests 79% upside potential

CG Oncology has surged 131% over the past year, with shares climbing 54% year-to-date and 20% in the last month to reach $64.29. The cancer-focused biotech has attracted investor attention amid progress in its pipeline. A discounted cash flow analysis suggests the stock may still be undervalued. The model projects free cash flow will shift from losses of $225 million in 2026 and $200 million in 2027 to positive $21 million in 2028, $340 million in 2029 and $590 million in 2030, based on analyst estimates through 2030. The DCF model estimates an intrinsic value of $304 per share, implying the current price is 79% undervalued according to this cash flow-based approach. CG Oncology scores three out of six on valuation checks.

Yahoo Finance
Mar 6th, 2026
H.C. Wainwright raises CG Oncology price target to $80, eyes Phase 3 PIVOT-006 trial as key 2026 catalyst

H.C. Wainwright has raised its price target on CG Oncology to $80 from $75, maintaining a Buy rating. The analyst cited the company's progress toward a biologics application submission for cretostimogene in high-risk non-muscle invasive bladder cancer, supported by strong safety and durability data. CG Oncology reported FY25 revenue of $4.04 million, exceeding the $515,180 consensus estimate. The company expects topline data from its Phase 3 PIVOT-006 trial in intermediate-risk NMIBC in the coming months, which H.C. Wainwright identified as a key 2026 catalyst. CEO Arthur Kuan described PIVOT-006 as the first randomised registrational trial evaluating an investigational therapy in intermediate-risk NMIBC. Results from the CORE-008 study evaluating cretostimogene combined with gemcitabine are expected next quarter.

Yahoo Finance
Feb 27th, 2026
CG Oncology expects PIVOT-006 Phase 3 data in H1 2026 with $903M cash to fund ops into 2029

CG Oncology reported its 2025 financial results, highlighting approximately $903 million in cash, cash equivalents and marketable securities, sufficient to fund operations into the first half of 2029. The company expects topline data from its PIVOT-006 Phase 3 trial evaluating cretostimogene as adjuvant therapy in intermediate-risk non-muscle invasive bladder cancer in the first half of 2026, nearly a year ahead of schedule. PIVOT-006 is the first randomised Phase 3 trial in this patient population. First results from CORE-008 Cohort CX, evaluating cretostimogene combined with gemcitabine in high-risk non-muscle invasive bladder cancer, are also expected in the first half of 2026. The company strengthened its board in November 2025 with the addition of Christina Rossi, former chief operating officer of Blueprint Medicines.

Business News Today
Apr 28th, 2025
CG Oncology reports best-in-disease durability data for cretostimogene at AUA 2025

CG Oncology reports best-in-disease durability data for cretostimogene at AUA 2025.

DealForma
Mar 19th, 2025
CG Oncology Raises $437M in IPO

In 2024, biopharma therapeutics and platforms saw significant IPO activity, raising $6.8 billion across 26 IPOs. Notable IPOs include CG Oncology's $437M in January, Kyverna Therapeutics' $367M in February, Bicara Therapeutics' $362M in August, Septerna's $331M in October, and Upstream Bio's $293M in September. Overall, the sector experienced increased deal activity and higher capital raised compared to 2023, indicating a stronger financing environment.

INACTIVE